Digital health company Nile AI has launched in Sherman Oaks, backed by a $25 million investment by Belgian pharmaceutical company UCB.

Privately-held Nile, which set up shop last month, is focused on developing a digital epilepsy care management platform for use by patients and neurologists between consultations, the company said in a statement.

The platform is currently in tests at Massachusetts General Hospital and Michigan State University Healthcare and will be commercially available later this year, Nile said.

“We believe that all of the data to predict the path of an epilepsy patient exists, though it is fragmented and disconnected,” Dr. Leo Petrossian, chief executive of Nile, said in a statement. “We are building a comprehensive care management system for addressing this uncertainty in the lives of people suffering from epilepsy.”

“UCB has a deep understanding of epilepsy and the challenges that people living with the disease face every day, including how patients communicate with their health care providers,” Charl Van Zyl, vice president and head of neurology solutions and international markets for UCB, said in a statement.

As a majority stakeholder in the tech company, UCB will have a seat on Nile’s board.